Patents by Inventor Stefanie Hammer

Stefanie Hammer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220125960
    Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being a PD-1/PD-L1 inhibitor, and component B being a targeted thorium conjugate. Another aspect of the present invention relates to the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of breast and prostate cancer.
    Type: Application
    Filed: February 17, 2020
    Publication date: April 28, 2022
    Applicants: Bayer Aktiengesellschaft, Bayer AS
    Inventors: Urs Beat HAGEMANN, Pascale LEJEUNE, Jenny KARLSSON, Alan CUTHBERTSON, Stefanie HAMMER
  • Publication number: 20220118123
    Abstract: The present invention covers combinations of at least two components, component A and component B, comprising component A being PSMA-TTC, and component B being an antiandrogen selected form AR antagonists such as from cyproterone acetate, bicalutamide, flutamide, nilutamide, enzalutamide, apalutamide, darolutamide or keto-darolutamide, or an AR degrader such as ARV-110, or an ARN-terminal domain binder such as EPI-506, or an antisense oligonucleotide that reduces AR expression such as EZN-4176 or AZD-5312, or an androgen synthesis inhibitor such as abiraterone, particularly abiraterone acetate, seviteronel, galeterone, orteronel or ketoconazole, or a dual AR antagonist and androgen synthesis inhibitor such as ODM-204. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of a hyper-proliferative disease.
    Type: Application
    Filed: February 17, 2020
    Publication date: April 21, 2022
    Applicants: Bayer Aktiengesellschaft, BAYER AS
    Inventors: Stefanie HAMMER, Urs Beat HAGEMANN, Bernard HAENDLER, Pascale LEJEUNE, Sabine ZITZMANN-KOLBE, Christoph SCHATZ, Jenny KARLSSON
  • Publication number: 20220016258
    Abstract: The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.
    Type: Application
    Filed: September 1, 2021
    Publication date: January 20, 2022
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Lisa DIETZ, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH, Sandra BERNDT, Anette SOMMER, Stefanie HAMMER
  • Publication number: 20210275686
    Abstract: The invention relates to a new binder-drug conjugates with improved properties, to active metabolites of said ADCs and to processes for the preparation thereof. The invention particularly relates to antibody-drug conjugates (ADCs) with CXCR5 antibodies and selected KSP inhibitors. The present invention further relates to the use of said conjugates for the treatment and/ore prevention of diseases and to the use of said conjugates for the production of medicaments for the treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases.
    Type: Application
    Filed: June 13, 2019
    Publication date: September 9, 2021
    Inventors: Sarah Anna Liesa JOHANNES, Hans-Georg LERCHEN, Beatrix STELTE-LUDWIG, Pascale LEJEUNE, Hannah JÖRISSEN, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH, Stefanie HAMMER
  • Patent number: 11071788
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: July 27, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Sven Wittrock, Sandra Berndt, Uwe Gritzan, Jenny Fitting, Beatrix Stelte-Ludwig, Patrick Jones, Christoph Mahlert, Christian Votsmeier, Dorian Schönfeld, Mark Trautwein, Ernst Weber, Nikolaus Pawlowski, Simone Greven, Julian Marius Glück, Stefanie Hammer, Lisa Dietz, Stephan Märsch
  • Publication number: 20210187134
    Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being an inhibitor of PI3K kinase, and component B being a targeted thorium conjugate. Another aspect of the present invention relates to the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of breast and prostate cancer.
    Type: Application
    Filed: August 23, 2019
    Publication date: June 24, 2021
    Applicants: Bayer AS, Bayer Aktiengesellschaft
    Inventors: Urs HAGEMANN, Stefanie HAMMER, Alan CUTHBERTSON
  • Publication number: 20200360531
    Abstract: Conjugate of a binder having formula: (A) wherein stands for a binder, Z? stands for a linker and D stands for an active component of Formula (I): and its use as pharmaceuticals.
    Type: Application
    Filed: January 25, 2019
    Publication date: November 19, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Niels BÖHNKE, Markus BERGER, Anette SOMMER, Stefanie HAMMER, Amaury Ernesto FERNANDEZ-MONTALVAN, Beatrix STELTE-LUDWIG, Judith GÜNTHER, Christoph MAHLERT, Simone GREVEN, Abul Basher SARKER, Michael TAIT
  • Publication number: 20200138970
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: June 20, 2016
    Publication date: May 7, 2020
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Sandra BERNDT, Uwe GRITZAN, Jenny FITTING, Beatrix STELTE-LUDWIG, Patrick JONES, Christoph MAHLERT, Christian VOTSMEIER, Dorian SCHÖNFELD, Mark TRAUTWEIN, Ernst WEBER, Nikolaus PAWLOWSKI, Simone GREVEN, Julian Marius GLÜCK, Stefanie HAMMER, Lisa DIETZ, Stephan MÄRSCH
  • Publication number: 20190365916
    Abstract: Specific binder-drug conjugates (ADCs) of kinesin spindle protein inhibitors, effective metabolites of these ADCs, processes for preparing these ADCs, the use of these ADCs for the treatment and/or prevention of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases, are described.
    Type: Application
    Filed: December 18, 2017
    Publication date: December 5, 2019
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Sandra BERNDT, Lisa DIETZ, Stephan MÄRSCH, Stefanie HAMMER
  • Publication number: 20190328897
    Abstract: The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.
    Type: Application
    Filed: December 14, 2017
    Publication date: October 31, 2019
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Lisa DIETZ, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH, Sandra BERNDT, Anette SOMMER, Stefanie HAMMER
  • Publication number: 20190298865
    Abstract: The invention provides a method for the formation of a tissue-targeting thorium complex, said method comprising; a) forming an octadentate chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N-position with a methyl group, and a coupling moiety terminating in a carboxylic acid group; b) coupling said octadentate chelator to at least one tissue-targeting moiety targeting prolyl endopeptidase FAP; and c) contacting said tissue-targeting chelator with an aqueous solution comprising an ion of at least one alpha-emitting thorium isotope. A method of treatment of a neoplastic or hyperplastic disease comprising administration of such a tissue-targeting thorium complex, as well as the complex and corresponding pharmaceutical formulations are also provided.
    Type: Application
    Filed: June 6, 2017
    Publication date: October 3, 2019
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AS
    Inventors: Alan CUTHBERTSON, Mark TRAUTWEIN, Ernst WEBER, Jenny KARLSSON, Stefanie HAMMER
  • Publication number: 20160237160
    Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the TWEAKR (TNFRSF12A, FN14). The antibodies, accordingly, can be used to treat tumors and other disorders and conditions associated with expression of the TWEAKR. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for us.
    Type: Application
    Filed: June 12, 2014
    Publication date: August 18, 2016
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Christian VOTSMEIER, Stefanie HAMMER, Uwe GRITZAN, Sandra BERNDT, Dmitry ZUBOV, Lars LINDEN, Sven CHRISTIAN, Axel HARRENGA, Jörg BIRKENFELD, Christoph FREIBERG, Sven GOLFIER, Andrea EICKER, Simone GREVEN, Beatrix STELTE-LUDWIG, Marian RASCHKE
  • Publication number: 20150023989
    Abstract: The present application relates to new antibody drug conjugates (ADCs) of N,N dialkylauristatins directed against the target FGFR2, drug metabolites of said ADCs, a method for producing said ADCs, the use of said ADCs for the treatment and/or prevention of illnesses as well as the use of said ADCs for producing pharmaceuticals for the treatment and/or prevention of illnesses, particularly of hyperproliferative and/or angiogenic diseases such as carcinosis. Such treatments can be carried out as monotherapy or in combination with other pharmaceuticals or additional therapeutic measures.
    Type: Application
    Filed: December 12, 2012
    Publication date: January 22, 2015
    Inventors: Hans-Georg Lerchen, Stefanie Hammer, Axel Harrenga, Charlotte Christine Kopitz, Carl Friedrich Nising, Anette Sommer, Beatrix Stelte-Luowig, Christoph Mahlert, Joachim Schuhmacher, Sven Golfier, Simone Greven, Sandra Bruder
  • Publication number: 20140322220
    Abstract: The present invention provides antibodies, or antigen-binding antibody fragments thereof, or variants thereof which reduce the cell surface expression of FGFR2 after binding to FGFR2 in both cells overexpressing FGFR2 and cells expressing mutated FGFR2. Also provided are antibody-based therapies for FGFR2-related diseases or conditions such as cancer. Antibodies of the invention also can be used in the diagnostics field. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: November 22, 2012
    Publication date: October 30, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Axel Harrenga, Charlotte Christine Kopitz, Stefanie Hammer, Frank Dittmer, Sven Golfier, Mark Trautwein, Sandra Bruder, Juergen Franz, Beatrix Stelte-Ludwig, Lars Linden, Ricarda Finnern, Simone Greven, Jan Tebbe
  • Publication number: 20090076098
    Abstract: The invention provides methods, kits and compounds for determining the potential responsiveness of a subject suffering from a pathological disorder, including non-small cell lung cancer (NSCLC), to treatment with an epothilone by analyzing the gene expression profile and/or certain molecular markers in a sample obtained from said subject. The invention further relates to methods, compounds and uses of said compounds for treating subjects suffering from said pathologic disorder, optionally in combination with other therapeutic agents. Also provided are genes and/or proteins encoded by them whose expression level have been determined to differ between epothilone responders and epothilone non-responders.
    Type: Application
    Filed: June 27, 2008
    Publication date: March 19, 2009
    Inventors: Jens Hoffmann, Stefanie Hammer, Anette Sommer